BioSpace News Archive

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlighting new data and insights related to neuronal itch mechanisms through eblasakimab’s targeting of IL-13Rα1 at the Society for Investigative Dermatology (SID) Annual Meeting.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, will provide an update on its business and address its 2023-2025 business growth strategy and financial goals during its 2022 Analyst & Investor Day today in New York City.

Apiary Medical, Inc. today announced the strategic acquisition of Manus Medical LLC, one of the leading SDVOSB providers of procedural packs for the federal government.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the X-Twist TM Knotless Fixation System.

Nutriband Inc., is pleased to announce that it has been invited to present at the Emerging Growth Conference on May 25, 2022.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5 th Global NASH Congress on May 26-27, 2022, in London, UK.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022.

Braxia Scientific Corp. a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders.

Sirnaomics Ltd. announced that the Company’s Executive Director and Chief Medical Officer, Dr. Michael Molyneaux, will present clinical study results of its leading product candidate STP705 for the treatment of non-melanoma skin cancers, and the Company’s clinical development strategy based on its strong presence in both the U.S. and China, at the 2022 Pre-ASCO China Summit.